Aldeyra Therapeutics, Inc.
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | +90.6% | +5.7% | +87.6% | +35.6% | -41.6% | +369.9% | -2.1% | +1.6% | -5.0% | +0.9% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +104.3% | +74.0% | +23.7% | +82.9% | +48.7% | -44.4% | +82.1% | +5.3% | -37.7% | +63.7% | -46.8% | |
| – | +23.9% | +25.0% | +12.1% | +59.7% | +23.1% | -17.8% | +13.0% | +36.3% | -13.3% | -10.8% | -19.3% | |
| – | +64.9% | +55.9% | +20.3% | +76.5% | +42.3% | -38.7% | +62.2% | +11.5% | -31.7% | +40.5% | -41.3% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -54.0% | -6.1% | +7.5% | +29.4% | +311.4% | +215.3% | -8.5% | -2.8% | +22.2% | -7.0% | -1.1% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -103.1% | – | +237.2% | +326.4% | -237.5% | – | – | -144.3% | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – |
Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.